Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Skotom-Perimetrie-Okulomotorik-Training (SPOT)

25. September 2026 aktualisiert von: Kristina M Visscher, University of Alabama at Birmingham

Neue Methoden zur Quantifizierung und zum Training von Augenbewegungsstrategien bei Makuladegeneration

The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight.

Declines in vision are particularly common in older adults and thus increasing our understanding of how to cre- ate effective means of improving vision is also highly relevant to the mission of the NIA to support research on aging and the health and well-being of older people.

Studienübersicht

Detaillierte Beschreibung

This proposal tests a novel 'scotoma awareness' approach to aid those with Macular Degeneration (MD). MD is the leading cause of central vision loss worldwide. MD patients spontaneously develop oculomotor strategies to overcome loss of central vision, such as developing a new peripheral fixation spot to replace the fovea (preferred retinal locus, or PRL). However, development of a PRL and the rate of success in developing one vary greatly, meaning some patients live years without making effective use of their spared vision. Recent, studies in Vision Science show that training healthy participants with gaze-contingent displays, obstructing central vision ('simulated scotoma'), leads to development of PRLs at a faster time scale than found for MD patients. Additionally, oculomotor metrics developed in our lab, are effective in characterizing individual eye movement patterns in simulated scotoma participants. The ability to describe differences in compensatory strategies in MD represents a crucial step towards individualized rehabilitative strategies, which could be further improved by accelerating PRL development. However, it is unclear whether these results can be reproduced in those with MD. It has been suggested that the visible, sharp-edged occluder in the gaze- contingent displays increases scotoma awareness, thus accelerating PRL development. Many MD patients are unaware of the location of their scotoma, with some persisting to use their damaged fovea as a fixation spot. No study to date has translated the use of a simulated scotoma to promote rapid PRL development in MD patients. As a first step towards addressing individual differences in patients and examine whether Vision Science paradigms can be used as a rehabilitative tool in MD, we propose two Aims: In Aim 1 we will use a set of oculomotor metrics to characterize individual profiles of compensation. In Aim 2 we will test the effectiveness of the visible, simulated scotoma as a technique to promote the rapid development of a PRL. Patients will undergo a 'scotoma awareness' training, in which a simulated scotoma, individually tailored for each patient, will be used to help them visualize their region of vision loss. Patients will be tested on the same metrics from Aim 1 and a battery of visual and cognitive assessments before and after the 'scotoma awareness' (or control) sessions. This will enable quantification of the effect of scotoma awareness both in terms of visual abilities and oculomotor strategies, and test the hypothesis that awareness of the location and extent of retinal damage promotes fast PRL development. While challenging, the use of eye tracking techniques in patients could be highly rewarding if this scotoma awareness procedure proves to be effective. A null result would be equally informative, suggesting fundamental differences between physiological and simulated scotomas, thus providing a limit in the use of simulations of retinal damage as a framework for the study of retinal pathologies such as MD. This will provide a unique data set to help those developing interventions for central vision loss understand how approaches to visual rehabilitation, and individual differences, give rise to training outcomes.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

21

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 89 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Severely impaired vision in both eyes (20/100 or worse)
  • Diagnosis of Macular Degeneration
  • Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (SLO, MAIA)
  • Medical record review indicates this disease severity level has been present for at least 2 years.

Exclusion Criteria:

  • Inability to sit still in eye tracker for extended periods
  • Inability to visualize iris on video eye tracker
  • Bilateral retinal scotomas larger than 20° diameter

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Condition 1 - 'Scotoma awareness' Training

Participants will be asked to report the emotion of an emoji face ('happy' vs 'sad') that could appear anywhere on screen. For the entire duration of the training, an explicit, sharp outlined occluder surrounding the participant's true retinal scotoma will be rendered on screen. This occluder will be generated through a gaze-contingent display. The size and the contrast of the target will change adaptively in response to the patient's performance.

In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.

Experimental: Condition 2 - Control Training

In the control condition, participants will perform the same task as the scotoma awareness training, without the artificial visible scotoma.

The task will be performed in the control group without the visible scotoma.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline Fixation Stability After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Dispersion of fixation locations averaged across trials in which the participant used their PRL (expressed as the Bivariate contour ellipse area (BCEA) of the dispersion of fixation locations).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Visual Acuity After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Score of Change in baseline visual acuity, in logMAR units after training. Measured as post-test minus pre-test.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Saccadic Re-referencing After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Proportion of trials with first fixation using PRL (expressed as a % of the total number of trials). Expressed as post-test minus pre-test.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline First Saccade Landing Dispersion After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The dispersion of the end point of the first saccade (expressed as the Bivariate contour ellipse area, BCEA of the dispersion). BCEA is the area (in deg^2) of an ellipse encompassing the fixation points, as described by Crossland et al., 2011.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Latency of Target Acquisition After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The mean time until target is visible outside scotoma (expressed in seconds).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Saccadic Precision After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

The dispersion of the end point of the saccade that puts the target outside scotoma (expressed as the BCEA of the dispersion).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Percentage of Trials That Are Useful After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

How often participants place the target outside of the scotoma (% of dots in Saccadic precision relative to total trials). Definition of "trials that are useful" is that the target is placed outside the scotoma at some point during the trial.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Minimal Print Size From MNREAD Task After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

For the MNREAD test we will primarily rely upon minimal print size (a secondary measure of acuity). MNREAD is a computerized version of the task from Mansfield et al., 1993 from Gordon Legge's lab. Participants perform the task without any simulated scotoma. Sentences are shown to participants in a standardized order, from largest to smallest. The words are read out loud. The task stops when the participant can no longer read the sentence. The number of sentences is thus a measure of how small the print can be for a participant to read it effectively. Larger number of sentences is a better minimal print size. Thus we expect that effective training will result in greater values at post-test than at baseline.

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Time-to-complete Trailmaking B Subtest After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

We will look at time-to-complete the Trail Making B subtest, measured in seconds. Post-test minus baseline. Trailmaking B test is often thought of as a measure of executive function. The task requires ordering numbers and letters, and switching between them (e.g., Find 1, then A, then 2, then B, then 3... etc.).

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Change From Baseline Contrast Sensitivity After Completion of Training at Approximately 6 Weeks and 14 Weeks
Zeitfenster: Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Measured via Robson-Pelli charts. Contrast sensitivity is a measure of what visual contrast the participant can detect. This outcome is in units of log contrast sensitivity

Baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. November 2022

Primärer Abschluss (Tatsächlich)

4. Juni 2025

Studienabschluss (Tatsächlich)

30. Juni 2025

Studienanmeldedaten

Zuerst eingereicht

7. Juli 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Juli 2022

Zuerst gepostet (Tatsächlich)

13. Juli 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. September 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Results of the project will be submitted to the relevant repository (ClinicalTrials.gov, or Open-Science Framework) within one year of the final participant completing data collection. We expect to report participant flow by group (intervention or control), participant demographics and other baseline characteristics, outcome measures and statistical analyses, adverse events (if applicable), and limitations or caveats of our results. We also will ensure that the final protocol and statistical analysis plan are uploaded to the record.

IPD-Sharing-Zeitrahmen

Results of the project will be submitted to the relevant repository (ClinicalTrials.gov, or Open-Science Framework) within one year of the final participant completing data collection.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ANALYTIC_CODE

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren